- Implied Volatility 16.99% ( +0.12%)
- Historical Volatility 19.82%
- IV Percentile 25%
- IV Rank 26.46%
- IV High 27.03% on 12/12/22
- IV Low 13.37% on 09/14/23
- Put/Call Vol Ratio 0.71
- Today's Volume 2,163
- Volume Avg (30-Day) 8,761
- Put/Call OI Ratio 2.99
- Today's Open Interest 138,975
- Open Int (30-Day) 125,523
Price PerformanceSee More
|Period||Period Low||Period High||Performance|
| || |
+7.39 (+6.41%)since 11/01/23
| || |
-7.41 (-5.70%)since 09/01/23
| || |
-14.56 (-10.62%)since 12/01/22
Most Recent StoriesMore News
If you invest over the long term, you'll increase your chances of victory.
Moderna stock continues to sag, even as new COVID variants emerge. However, investors may be underestimating the potential of the mRNA pipeline.
As the IBB ETF nears a potential breakout, watch for strong performers like Regeneron Pharmaceuticals, Vertex, and Exelixis to continue outperforming.
These exchange-traded funds (ETFs) offer low or ultralow net expense ratios and are perfectly positioned to help investors grow their wealth.
These three exchange-traded funds could be winning plays for patient investors.
The health care space has proven to be one of the more explosive opportunities for investors in the ...
Moderna's value has declined by over 75% from its peak as the world moves on from the COVID-19 pandemic, leading to concerns about its investment appeal.
The current consolidation in the IBB signals a potential breakout might be looming as key moving averages have converged within a contracted price range.
2023 could be a year of heightened biotech dealmaking activity